Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Capital Expenditures (2016)

Eledon Pharmaceuticals filings provide 4 years of Capital Expenditures readings, the most recent being -$3000.0 for Q4 2016.

  • On a quarterly basis, Capital Expenditures fell 101.39% to -$3000.0 in Q4 2016 year-over-year; TTM through Dec 2016 was $9000.0, a 98.41% decrease, with the full-year FY2016 number at $9000.0, down 98.41% from a year prior.
  • Capital Expenditures hit -$3000.0 in Q4 2016 for Eledon Pharmaceuticals, down from $2000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $216000.0 in Q4 2015 to a low of -$7000.0 in Q2 2016.
  • Median Capital Expenditures over the past 4 years was $9500.0 (2014), compared with a mean of $50250.0.
  • Biggest five-year swings in Capital Expenditures: surged 2350.0% in 2015 and later plummeted 104.76% in 2016.
  • Eledon Pharmaceuticals' Capital Expenditures stood at $4000.0 in 2013, then soared by 75.0% to $7000.0 in 2014, then surged by 2985.71% to $216000.0 in 2015, then crashed by 101.39% to -$3000.0 in 2016.
  • The last three reported values for Capital Expenditures were -$3000.0 (Q4 2016), $2000.0 (Q3 2016), and -$7000.0 (Q2 2016) per Business Quant data.